Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report

Kawasaki,Kenta; Hamamoto,Yasuo; Suzuki,Takeshi; Hirata,Kenro; Sukawa,Yasutaka; Kasuga,Akiyoshi; Hayashi,Yuichiro; Takaishi,Hiromasa; Kameyama,Kaori; Kanai,Takanori

doi:10.3892/ol.2017.6601

Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report

Authors:
- Kenta Kawasaki
- Yasuo Hamamoto
- Takeshi Suzuki
- Kenro Hirata
- Yasutaka Sukawa
- Akiyoshi Kasuga
- Yuichiro Hayashi
- Hiromasa Takaishi
- Kaori Kameyama
- Takanori Kanai
View Affiliations

Affiliations: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160‑8582, Japan, Keio Cancer Center, Keio University School of Medicine, Tokyo 160‑8582, Japan, Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo 160‑8582, Japan
Published online on: July 18, 2017 https://doi.org/10.3892/ol.2017.6601
Pages: 3697-3700

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rebiopsy is considered an option for specific types of cancer, such as breast, non‑small cell lung, and prostate cancer, in clinical trials and in practice. The benefit of rebiopsy comes from the selection of a new treatment strategy based on the genetic profile of the cells, which may reflect the development of drug resistance or hormonal changes. For colorectal cancer, the presence of different genomic mutations between the primary tumor and its metastases is rare, and rebiopsy is therefore not generally performed. The present study reports the case of a 68‑year‑old man who was initially diagnosed with metastatic adenocarcinoma from a primary colorectal cancer, but was subsequently rediagnosed with metastatic neuroendocrine carcinoma based on the pathological rebiopsy results. The patient responded well to cisplatin and etoposide treatment, after not responding to initial FOLFOX treatment. In this case, rebiopsy resulted in a change in treatment regimen and improved the patient's quality of life and his long‑term survival. This case indicates that, when a colorectal cancer patient is unresponsive to standard treatment, it may be beneficial for the clinician to suspect an atypical histological type, and to consider rebiopsy.

View Figures

View References

1	National Comprehensive Cancer Network, . NCCN Clinical Practice Guidelines in OncologyInvasive Breast Cancer. version 3; BINV-17, MS-45. Fort Washington: 2015
2	National Comprehensive Cancer Network (NCCN), . NCCN Clinical Practice Guidelines in OncologyNon Small Cell Lung Cancer. version 1. Fort Washington: NSCL-16; 2016
3	National Comprehensive Cancer Network, . NCCN Clinical Practise Guidelines in OncologyProstate Cancer. version 1; PROS-9, MS-32. Fort Washington: 2016
4	National Comprehensive Cancer Network, . NCCN Clinical Practice Guidelines in OncologyColon Cancer. version 1; COL-9, 11, COL-C 1 of 9. Fort Washington: 2016
5	National Comprehensive Cancer Network, . NCCN Clinical Practice Guidelines in OncologyRectal Cancer. version 1. REC-9, 11, MS37-MS38. Fort Washington: 2016
6	Bernick PE, Klimstra DS, Shia J, Minsky B, Saltz L, Shi W, Thaler H, Guillem J, Paty P, Cohen AM and Wong WD: Neuroendocrine carcinomas of the colon and rectum. Dis Colon Retum. 47:163–169. 2004. View Article : Google Scholar
7	Shafqat H, Ali S, Salhab M and Olszewski AJ: Survival of patients with neuroendocrine carcinoma of the colon and rectum: A population-based analysis. Dis Colon Rectum. 58:294–303. 2015. View Article : Google Scholar : PubMed/NCBI
8	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
9	Volante M, Marci V, Andrejevic-Blant S, Tavaglione V, Sculli MC, Tampellini M and Papotti M: Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas. Virchows Arch. 457:521–527. 2010. View Article : Google Scholar : PubMed/NCBI
10	Shia J, Tickoo SK, Guillem JG, Qin J, Nissan A, Hoos A, Stojadinovic A, Ruo L, Wong WD, Paty PB, et al: Increased endocrine cells in treated rectal adenocarcinomas: A possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapy. Am J Surg Pathol. 26:863–872. 2002. View Article : Google Scholar : PubMed/NCBI
11	Tampellini M, Brizzi MP, Bitossi R, Alabiso I, Sculli CM, Chiusa L, Papotti M and Dogliotti L: Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy. J Cancer Res Clin Oncol. 133:783–785. 2007. View Article : Google Scholar : PubMed/NCBI
12	Tagawa ST: Neuroendocrine prostate cancer after hormonal therapy: Knowing is half the battle. J Clin Oncol. 32:3360–3364. 2014. View Article : Google Scholar : PubMed/NCBI
13	Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB and Thompson AM: Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 38:708–714. 2012. View Article : Google Scholar : PubMed/NCBI
14	Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G and Clemons MJ: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 20:1499–1504. 2009. View Article : Google Scholar : PubMed/NCBI
15	Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, et al: Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 33:2695–2704. 2015. View Article : Google Scholar : PubMed/NCBI
16	Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, et al: ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 25:1871–1888. 2014. View Article : Google Scholar : PubMed/NCBI
17	Sun JM, Ahn MJ, Choi YL, Ahn JS and Park K: Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer. 82:294–298. 2013. View Article : Google Scholar : PubMed/NCBI
18	Chouaid C, Dujon C, Do P, Monnet I, Madroszyk A, Le Caer H, Auliac JB, Berard H, Thomas P, Lena H, et al: Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12–01). Lung Cancer. 86:170–173. 2014. View Article : Google Scholar : PubMed/NCBI
19	Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, et al: Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 346:1480–1486. 2014. View Article : Google Scholar : PubMed/NCBI
20	Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, Rubin MA and Nanus DM: Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 30:e386–e389. 2012. View Article : Google Scholar : PubMed/NCBI
21	Tórtola S, Steinert R, Hantschick M, Peinado MA, Gastinger I, Stosiek P, Lippert H, Schlegel W and Reymond MA: Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol. 19:2837–7843. 2001. View Article : Google Scholar : PubMed/NCBI
22	Zauber P, Sabbath-Solitare M, Marotta SP and Bishop DT: Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol. 56:137–140. 2003. View Article : Google Scholar : PubMed/NCBI
23	Albanese I, Scibetta AG, Migliavacca M, Russo A, Bazan V, Tomasino RM, Colomba P, Tagliavia M and La Farina M: Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun. 325:784–791. 2004. View Article : Google Scholar : PubMed/NCBI
24	Baas JM, Krens LL, Guchelaar HJ, Morreau H and Gelderblom H: Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: A review. Oncologist. 16:1239–1249. 2011. View Article : Google Scholar : PubMed/NCBI
25	Khasraw M, Brogi E and Seidman AD: The need to examine metastatic tissue at the time of progression of breast cancer: Is rebiopsy a necessity or a luxury? Curr Oncol Rep. 13:17–25. 2011. View Article : Google Scholar : PubMed/NCBI
26	Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM and Peters S: ESMO Guidelines Working Group: Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25:(Suppl 3). iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
27	Palmgren JS, Karavadia SS and Wakefield MR: Unusual and underappreciated: Small cell carcinoma of the prostate. Semin Oncol. 34:22–29. 2007. View Article : Google Scholar : PubMed/NCBI